Cargando…

Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study

Background: In recent times, different novel GnRH-antagonist protocols with various combinations of gonadotropins and other molecules (e.g., aromatase inhibitors, selective estrogen receptor modulators) have been proposed for expected normal ovarian responders undergoing assisted reproductive treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amato, Giuseppe, Caringella, Anna Maria, Stanziano, Antonio, Cantatore, Clementina, D’Amato, Antonio, Cicinelli, Ettore, Vitagliano, Amerigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092944/
https://www.ncbi.nlm.nih.gov/pubmed/37046467
http://dx.doi.org/10.3390/diagnostics13071249
_version_ 1785023466460676096
author D’Amato, Giuseppe
Caringella, Anna Maria
Stanziano, Antonio
Cantatore, Clementina
D’Amato, Antonio
Cicinelli, Ettore
Vitagliano, Amerigo
author_facet D’Amato, Giuseppe
Caringella, Anna Maria
Stanziano, Antonio
Cantatore, Clementina
D’Amato, Antonio
Cicinelli, Ettore
Vitagliano, Amerigo
author_sort D’Amato, Giuseppe
collection PubMed
description Background: In recent times, different novel GnRH-antagonist protocols with various combinations of gonadotropins and other molecules (e.g., aromatase inhibitors, selective estrogen receptor modulators) have been proposed for expected normal ovarian responders undergoing assisted reproductive treatments. The purpose of this study was to evaluate the effectiveness of a novel ovarian stimulation protocol based on the combination of corifollitropin-alfa plus five days of letrozole in E-NOR women undergoing IVF as compared with a daily recombinant-FSH regimen. Methods: We conducted a retrospective-controlled study on 182 couples undergoing their first IVF attempt. In Group A (experimental), letrozole (2.5 mg daily) was administered from day 2 (up to day 6 of the cycle), followed by corifollitropin-alfa on day 3 and daily recombinant FSH from day 10. In Group B, recombinant FSH from day 2 were administered (150 IU-225 IU daily). Statistical analysis was completed using SPSS Statistics. The primary outcome was the total number of MII oocytes retrieved. Results: Group A showed similar results compared to Group B in terms of MII oocytes, live birth, implantation, and clinical pregnancy rates (p = ns). Nevertheless, the experimental group was associated with a trend towards a higher number of developing follicles, total oocytes, and embryos (p < 0.05) with lower estradiol and progesterone values at ovulation induction compared to Group B, resulting in an increased chance of performing a fresh embryo transfer (p < 0.05). Conclusions: The combination of CFα plus five days of letrozole was associated with a trend towards a higher number of developing follicles, total oocytes, and obtained embryos. Moreover, the experimental protocol resulted in lower estradiol and progesterone values at ovulation induction compared to daily rFSH, with an increased chance of performing a fresh embryo transfer (with no OHSS occurrence). Given the observational design of our study, further well-conducted RCTs are needed.
format Online
Article
Text
id pubmed-10092944
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100929442023-04-13 Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study D’Amato, Giuseppe Caringella, Anna Maria Stanziano, Antonio Cantatore, Clementina D’Amato, Antonio Cicinelli, Ettore Vitagliano, Amerigo Diagnostics (Basel) Article Background: In recent times, different novel GnRH-antagonist protocols with various combinations of gonadotropins and other molecules (e.g., aromatase inhibitors, selective estrogen receptor modulators) have been proposed for expected normal ovarian responders undergoing assisted reproductive treatments. The purpose of this study was to evaluate the effectiveness of a novel ovarian stimulation protocol based on the combination of corifollitropin-alfa plus five days of letrozole in E-NOR women undergoing IVF as compared with a daily recombinant-FSH regimen. Methods: We conducted a retrospective-controlled study on 182 couples undergoing their first IVF attempt. In Group A (experimental), letrozole (2.5 mg daily) was administered from day 2 (up to day 6 of the cycle), followed by corifollitropin-alfa on day 3 and daily recombinant FSH from day 10. In Group B, recombinant FSH from day 2 were administered (150 IU-225 IU daily). Statistical analysis was completed using SPSS Statistics. The primary outcome was the total number of MII oocytes retrieved. Results: Group A showed similar results compared to Group B in terms of MII oocytes, live birth, implantation, and clinical pregnancy rates (p = ns). Nevertheless, the experimental group was associated with a trend towards a higher number of developing follicles, total oocytes, and embryos (p < 0.05) with lower estradiol and progesterone values at ovulation induction compared to Group B, resulting in an increased chance of performing a fresh embryo transfer (p < 0.05). Conclusions: The combination of CFα plus five days of letrozole was associated with a trend towards a higher number of developing follicles, total oocytes, and obtained embryos. Moreover, the experimental protocol resulted in lower estradiol and progesterone values at ovulation induction compared to daily rFSH, with an increased chance of performing a fresh embryo transfer (with no OHSS occurrence). Given the observational design of our study, further well-conducted RCTs are needed. MDPI 2023-03-27 /pmc/articles/PMC10092944/ /pubmed/37046467 http://dx.doi.org/10.3390/diagnostics13071249 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
D’Amato, Giuseppe
Caringella, Anna Maria
Stanziano, Antonio
Cantatore, Clementina
D’Amato, Antonio
Cicinelli, Ettore
Vitagliano, Amerigo
Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study
title Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study
title_full Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study
title_fullStr Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study
title_full_unstemmed Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study
title_short Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study
title_sort corifolitropin-alfa plus five days letrozole versus daily recombinant-fsh in expected normo-responder patients: a retrospective comparative study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092944/
https://www.ncbi.nlm.nih.gov/pubmed/37046467
http://dx.doi.org/10.3390/diagnostics13071249
work_keys_str_mv AT damatogiuseppe corifolitropinalfaplusfivedaysletrozoleversusdailyrecombinantfshinexpectednormoresponderpatientsaretrospectivecomparativestudy
AT caringellaannamaria corifolitropinalfaplusfivedaysletrozoleversusdailyrecombinantfshinexpectednormoresponderpatientsaretrospectivecomparativestudy
AT stanzianoantonio corifolitropinalfaplusfivedaysletrozoleversusdailyrecombinantfshinexpectednormoresponderpatientsaretrospectivecomparativestudy
AT cantatoreclementina corifolitropinalfaplusfivedaysletrozoleversusdailyrecombinantfshinexpectednormoresponderpatientsaretrospectivecomparativestudy
AT damatoantonio corifolitropinalfaplusfivedaysletrozoleversusdailyrecombinantfshinexpectednormoresponderpatientsaretrospectivecomparativestudy
AT cicinelliettore corifolitropinalfaplusfivedaysletrozoleversusdailyrecombinantfshinexpectednormoresponderpatientsaretrospectivecomparativestudy
AT vitaglianoamerigo corifolitropinalfaplusfivedaysletrozoleversusdailyrecombinantfshinexpectednormoresponderpatientsaretrospectivecomparativestudy